PRODUCTS SOLD BY ASCEND PEPTIDES ARE INTENDED FOR RESEARCH USE ONLY.
Laboratory research material
MOTS-C 40mg (mitochondrial-derived peptide MOTS-c, also written MOTSc, CAS 1627580-64-6) supplied as a lyophilised powder in a single sealed vial for laboratory research. The larger format, for extended studies and multi-assay designs run from one batch. Janoshik report published for this format. For in-vitro research use only.
Research guide: What Is MOTS-C? · Smaller format: MOTS-C 10mg
Safety information: Not intended for human or veterinary use. Use appropriate laboratory safety procedures when handling.
MOTS-C 40mg should only be used in laboratory settings by qualified personnel.
Ensure all experimental procedures comply with local and institutional regulations.
This peptide is supplied for research and scientific study purposes only.
Janoshik test #125392 was run on one vial labelled MOTS-C 40mg from batch 20260114, analysis dated 7 April 2026. It reported a purity of 99.391% and a measured MOTS-c content of 43.66 mg for that vial. View the report on janoshik.com (verification key IKFY5JSKQTKY).
Purity and measured content are different results: purity is the share of detected material that is MOTS-c, and does not by itself establish quantity. The report covers one vial; it does not show that every vial or batch gives the same result, and whether the batch reference identifies a production batch matching current stock is still being confirmed. The report does not state the analytical method. It applies to the 40mg format only and does not verify 10mg vials.
MOTS-C 40mg
MOTS-C 40mg is the larger vial of MOTS-c, a 16-amino-acid peptide encoded by a short open reading frame in the mitochondrial 12S rRNA gene. Ascend Peptides UK supplies it as a lyophilised powder in a sealed vial for laboratory research only. It suits larger single-batch studies than the MOTS-C 10mg vial.
Both vials contain the same peptide. The 40mg vial suits larger experimental designs, longer studies and work where several assays should draw on one vial and one batch. The MOTS-C 10mg vial suits pilot work and method development. Of the two formats, only the 40mg vial has a published certificate.
MOTS-c was described in 2015 as a peptide encoded within the mitochondrial 12S rRNA. In cell and mouse studies it inhibited the folate cycle and de novo purine synthesis, which led to AMPK activation, and its main target tissue appeared to be skeletal muscle (Lee et al., 2015). Later cell work reported that MOTS-c moves to the nucleus under metabolic stress, in an AMPK-dependent way, and regulates nuclear genes (Kim et al., 2018). In mice, MOTS-c treatment was reported to improve physical performance; in humans, the same study measured higher endogenous MOTS-c after exercise but did not give MOTS-c to people (Reynolds et al., 2021).
These are findings about the compound in the published literature, mainly from cell and animal models. They are not properties tested on this product and do not describe any outcome in humans. A fuller explanation is in What Is MOTS-C?
A Janoshik report for one tested vial of MOTS-C 40mg is published on the CoA page, where the batch reference, results and verification details for that vial are listed.
Purity and content are different results. Purity is the share of detected material that is MOTS-c. Content is how much MOTS-c was measured in the vial. Each report covers one vial from one batch: it does not show that every vial or batch gives the same result, and whether a report’s batch reference identifies a production batch, and matches current stock, is still being confirmed with the manufacturer. The report does not state the analytical method used and lists no separate mass-spectrometry identity test.
The identifiers above (sequence, formula, molecular weight, CAS, UNII, PubChem and UniProt numbers) are reference values for the MOTS-c peptide from PubChem, the NCATS substance registry and UniProt. They describe the compound, not test results for a particular vial, and they refer to the free peptide; the salt form supplied (for example acetate or trifluoroacetate) has not yet been confirmed by the manufacturer.
Storage requirements for this product are being verified with the manufacturer. Please contact ASCEND before purchasing for information about the current product batch.
For in-vitro laboratory research only. Not for human consumption. Not an MHRA-licensed medicine.
MOTS-C 40mg is supplied strictly for in-vitro laboratory research and not for human use. It is not a medicine, is not an MHRA-licensed product, and is not supplied or marketed for diagnostic, therapeutic or clinical use in humans or animals. MOTS-c is prohibited at all times under the World Anti-Doping Agency Prohibited List, where it is named under S4.4.1 (AMPK activators).
Other laboratory research materials supplied by Ascend Peptides UK.
UK same working-day dispatch – Secure payment options –
Laboratory research only
© 2026 by Ascend Peptides Uk.
All products sold by Ascend Peptides UK are intended strictly for laboratory research purposes only. Not intended for human consumption or therapeutic use of any kind.
Per product, applied automatically in your bagAuto-applied in your bag
Ordering more? Contact us for larger-volume pricing →